Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Molecular Cancer Therapeutics|2025Cited by 20
Supplementary Figure S3 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Hannah Stowe et al.|Unknown|2025Cited by 0
Supplementary Table S4 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Unknown|2025Cited by 0
Supplementary Table S10 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Unknown|2025Cited by 0
Supplementary Table S7 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Unknown|2025Cited by 0